Literature DB >> 23485133

The role of thymidine kinase in cancer diseases.

Ondrej Topolcan1, Lubos Holubec.   

Abstract

Thymidine kinase 1 (TK 1-fetal) is a cell cycle-dependent marker that increases dramatically during the S-phase of the cell cycle. In this review, the authors discuss serum levels of thymidine kinase in a variety of neoplasias. Determination of thymidine kinase helps to monitor the follow-up of solid tumours and haematological malignancies as well as indicating the efficacy of adjuvant and palliative chemotherapy. Elevated levels of thymidine kinase must always be interpreted together with a detailed knowledge of the patient's condition because nonspecific elevations of serum levels (inflammatory and autoimmune diseases) must be excluded.

Entities:  

Year:  2008        PMID: 23485133     DOI: 10.1517/17530059.2.2.129

Source DB:  PubMed          Journal:  Expert Opin Med Diagn        ISSN: 1753-0059


  28 in total

1.  High thymidine kinase 1 (TK1) expression is a predictor of poor survival in patients with pT1 of lung adenocarcinoma.

Authors:  Yan Xu; Qun-Li Shi; Henghui Ma; Hangbo Zhou; Zhenfeng Lu; Bo Yu; Xiaojun Zhou; Staffan Eriksson; Ellen He; Sven Skog
Journal:  Tumour Biol       Date:  2011-12-06

2.  Antitumor effect of the LIVP-GFP recombinant vaccinia virus.

Authors:  I S Petrov; E P Goncharova; I V Kolosova; S G Pozdnyakov; S N Shchelkunov; M A Zenkova; V V Vlasov
Journal:  Dokl Biol Sci       Date:  2013-08-24

3.  Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1,247 cancer patients in routine clinical settings.

Authors:  Yan Chen; Mingang Ying; YanSong Chen; Minhua Hu; Yingying Lin; Dedong Chen; Xiaoli Li; Ming Zhang; Xia Yun; Ji Zhou; Ellen He; Sven Skog
Journal:  Int J Clin Oncol       Date:  2010-04-01       Impact factor: 3.402

4.  Serum thymidine kinase 1 concentration as a prognostic factor of chemotherapy-treated non-Hodgkin's lymphoma patients.

Authors:  Zhu-Lin Pan; Xing-Ying Ji; Yan-Min Shi; Ji Zhou; Ellen He; Sven Skog
Journal:  J Cancer Res Clin Oncol       Date:  2010-02-07       Impact factor: 4.553

5.  Effect of NK cell immunotherapy on immune function in patients with hepatic carcinoma: A preliminary clinical study.

Authors:  Zilin Qin; Jibing Chen; Jianying Zeng; Lizhi Niu; Silun Xie; Xiaohua Wang; Yingqing Liang; Zhenyi Wu; Mingjie Zhang
Journal:  Cancer Biol Ther       Date:  2017-03-29       Impact factor: 4.742

6.  [Loss of appetite, night sweats, eczema, and axillary and inguinal lymph node swelling in a 28-year-old man].

Authors:  U Wahl; R Stranzenbach; I Tischoff; A Tannapfel; R Stadler; F Ernst
Journal:  Internist (Berl)       Date:  2014-03       Impact factor: 0.743

7.  Serum thymidine kinase 1 activity in solid tumor (breast and colorectal cancer) patients treated with adjuvant chemotherapy.

Authors:  M Bolayirli; C Papila; G G Korkmaz; B Papila; F Aydoğan; A Karataş; H Uzun
Journal:  J Clin Lab Anal       Date:  2013-05       Impact factor: 2.352

Review 8.  The proliferation marker thymidine kinase 1 in clinical use.

Authors:  Ji Zhou; Ellen He; Sven Skog
Journal:  Mol Clin Oncol       Date:  2012-09-04

9.  Serum thymidine kinase 1 levels correlate with clinical characteristics of esophageal squamous cell carcinoma.

Authors:  Yong Ji; Xiao-Bo Wu; Jing-Yu Chen; Bin Hu; Qian-Kun Zhu; Xing-Feng Zhu; Min-Feng Zheng
Journal:  Int J Clin Exp Med       Date:  2015-08-15

10.  Serum thymidine kinase 1 protein concentration for predicting early progression and monitoring the response to TACE in hepatocellular carcinomas: a network meta-analysis.

Authors:  Hongbo Ma; Ailian Hei; Ji Zhou; Ellen He; Sven Skog; Jin Li
Journal:  Future Sci OA       Date:  2021-05-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.